Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes.
Journal: Clinical and translational science
Published: August 01, 2025
Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis.
Journal: Clinical and translational science
Published: October 02, 2024
Safety and Efficacy of Copanlisib in Combination with Nivolumab: A Phase Ib Study in Patients with Advanced Solid Tumors.
Journal: Cancer research communications
Published: September 03, 2024
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.
Journal: Clinical and translational science
Published: August 29, 2024
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 09, 2023
Model-Based Benefit/Risk Analysis for the Copanlisib Intermittent Dosing Regimen.
Journal: Clinical pharmacology and therapeutics
Published: September 12, 2023
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Journal: CPT: pharmacometrics & systems pharmacology
Published: January 27, 2023
Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.
Journal: Clinical and translational science
Published: January 04, 2023
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 11, 2021
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 08, 2021
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 19, 2021
Last Updated: 09/26/2026